
Aptevo Therapeutics fell 98.1% from $23.76 to $0.45, behind the S&P 500's +10.6%. Its worst day was Dec 26 (−34.7%), and its low came Nov 18 at $0.45.
Nov 18, 2025 – Nov 18, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Aptevo Therapeutics closed at its highest level of the year, 5.3% above where the year started.
+0.7% · S&P 500 +0.1%
Aptevo Therapeutics shares fell 34.7%, while the S&P 500 fell 0.0%.
Story events cover the past 12 months · Times ET
−34.7%, the year's worst day · S&P 500 0.0%
Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy alongside venetoclax + azacitidineSEATTLE, WA / ACCESS Newswire / March 10, 2026 / Aptevo Therapeutics Inc.
−21.2% · S&P 500 −0.2%
EPS of $-6.23 beat the $-8.09 estimate on $0.00 revenue.
+0.9% · S&P 500 −1.8%
EPS of $-6.41 missed the $-5.60 estimate on $0.00 revenue.
+0.7% · S&P 500 +0.8%
EPS of $-5.31 beat the $-6.16 estimate on $0.00 revenue.
−13.8% · S&P 500 −0.2%
Remission results nearly double published ven/aza outcomes in patients with historically limited treatment success
−34.2% · S&P 500 +1.0%
EPS of $-5.19 missed the $-3.58 estimate on $0.00 revenue.
−7.7% · S&P 500 −1.9%
Where it ended: a close of $0.45 on Nov 18, 2026.
Nothing in the past 12 months.
All APVO analyst actionsNothing in the past 12 months.
All APVO dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for APVO and SPY from Benzinga historical bars. Not investment advice.